March 30, 2023 4:53pm
Wednesday’s upside was wiped clean Thursday by diminishing sentiment; as I have stated, “What goes up with ceremony, goes down with disdain” as Q1 comes to a close on Friday (3/31)
Is Avrobio (AVRO -$0.0333 to $0.93 after Wednesday’s -$0.08 headed to be de-listed (below the $1.00 requirement of Nasdaq) – again?
Pre-open Indications: 8 Hits and 1 Miss
Earnings: Brainstorm Cell Therapeutics (BCLI) reports FY22 net loss and per share loss with only $3 M left in till which runs-out in Q3/23 <Q4/22 not reported – WHY?>
I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about - truth!
Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed UP +141.43 points (+0.43%), the S&P closed UP +23.02 points (+0.57%) while the Nasdaq closed UP +87.24 points (+0.73%)
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes rolled, weekly jobless claims increased as investors and depositors tried to forget the collapse of Silicon Valley Bank (SVB) most having “got” their money -- OUT.
Economic Data Docket: Weekly jobless claims increased by 7,000 to 198,000, adding to hopes that the Fed could slow down its tightening campaign because the labor market is cooling.
Pre-open Indications: 8 Hits < Voyager Therapeutics (VYGR +$0.12), CRISPR Therapeutics (CRSP -$1.02), Caribou Biosciences (CRBU -$0.03), Verve Therapeutics (VERV -$0.48), Chinook Therapeutics (KDNY -$0.32), Ionis Pharmaceuticals (IONS -$0.59), Sage Therapeutics (SAGE -$1.83), Ultragenyx (RARE -$0.43)> and 1 Miss < Beam Therapeutics (BEAM -$0.87),
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences
- Thursday’s advance/decline line opened negative at 9 up/ 25 down and 1 flat, stayed negative with 6 up/ 29 down and 0 flat at the mid-day, ending with a negative close of 8/27 and 0 flat
All time low:
- bluebird bio (BLUE) at $3.14
- Regenxbio (RGNX) at $18.08
RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … https://www.regmedinvestors.com/articles/12843 - 31 of 35 – added BCLI and ADVM
Key Metrics:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Thursday, the IBB was down -0.47% and the XBI was down -2.16%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Thursday was down -0.04 points or -0.21% at 19.08
Closing Down (10 of 27):
- Sage Therapeutics (SAGE -$1.83 after Wednesday’s +$1.96, Tuesday’s -$1.60 and Monday’s +$0.47),
- Intellia Therapeutics (NTLA -$1.54 after Wednesday’s +$1.54, Tuesday’s -$1.13 and Monday’s -$1.15),
- CRISPR Therapeutics (CRSP -$1.02 after Wednesday’s +$1.33, Tuesday’s -$0.50 and Monday’s +$0.92),
- Beam Therapeutics (BEAM -$0.87 after Wednesday’s +$0.86 and Tuesday’s -$0.38),
- Regenxbio (RGNX -$0.87),
- Alnylam Pharmaceuticals (ALNY -$0.79 after Wednesday’s +$7.36, Tuesday’s -$1.96 and Monday’s +$0.53),
- Ionis Pharmaceuticals (IONS -$0.59 after Wednesday’s +$1.19 and Monday’s -$0.23),
- Vericel (VCEL -$0.53 after Wednesday’s +$0.60 after Tuesday’s -$0.92),
- Verve Therapeutics (VERV -$0.48),
- Ultragenyx (RARE -$0.43 after Wednesday’s +$1.41, Tuesday’s +$0.33 and Monday’s -$0.35),
Closing Up (8 of 8):
- Solid Biosciences (SLDB +$0.13),
- Voyager therapeutics (VYGR +$0.12),
- AxoGen (AXGN +$0.12),
- Cellectis SA (CLLS +$0.11),
- Brainstorm Cell Therapeutics (BCLI +$0.06),
- Biostage (OTCQB: BSTG +$0.05 after Wednesday’s +$0.16, Tuesday’s -$0.51 and Monday’s $0.00),
- Mesoblast (MESO +$0.02),
- Bellicum Pharmaceuticals (BLCM +$0.018),
Q1/23 – March
- Thursday closed negative with 8 incliner, 27 decliners and 0 flat
The BOTTOM LINE: I try to keep it simple … and short!
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
Fear is the trade …
Markets jumped, sector dumped – economic “trouble” is ahead; leaving the cell and gene therapy “universe” in a precarious position – clinical news is more than due to substantiate any movement forward/upward.
Lately when is see gains, I know that pain is coming!
The real focus is … WHEN will sustainability become a component of this period.
The rush of Q4 and FY22 earnings to release has slowed as … 30 of my 35 covered have reported as upcoming Q4 earnings reporting will present challenges to share pricing.
- Brainstorm Cell Therapeutics (BCLI) reported FY22 net losses only today,
- Adverum Biotechnologies (ADVM) reported Q4 and FY22 net losses also
- Five (5) more releases forthcoming of my 35 covered companies
WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.
Remember, there are four (4) phases of the stock cycle: accumulation; markup; distribution; and markdown.
What I knew that I didn’t write about after bluebird bio’s (BLUE) earnings on Wednesday and its subsequent decline:
· BLUE revealed that its experimental sickle cell disease therapy might experience a slight regulatory delay.
· Blue also has less than two years of cash.
· A substantiating and back-up quote from George Budwell, Motley Fool – “Investors hit the exits after the company revealed that it may miss the first-quarter submission goal for lovo-cel's Biologics License Application (BLA) to the Food and Drug Administration (FDA). Lovo-cel is an experimental gene therapy in development for the rare blood disorder sickle cell disease.”
I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.
The NO spin zone!
Biostage (OTCQB: BSTG) – still pumping the volume and TRYING to promote the share price!!
Thursday closed up +$0.05 with 2,298 shares traded after Wednesday closed up +$0.16 with 1,200 shares traded, Tuesday closed down -$0.51 with 3,895 shares traded and Monday closed flat with 25 shares traded <3-month average volume = 1,736 shares>
· Question: Review the number of shares traded … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold??
· Let’s also welcome a NEW accounting firm – the fourth (4th) in five (5) years. When will they resign …??
· Where is the SEC??
· NEW Auditors must consider whether there is substantial doubt about a company’s ability to continue as a going concern, an assessment of the company’s viability over the next year.
· As OTCQB: BSTG continues as an “going concern”!
My question that resounds, that should be asked is how many companies are at the end of sentiments … leash?
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
